MedTrace Logo

Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

NCT02885818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-04-19

No results posted yet for this study

Summary

Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential effects on B cells are not well described. This study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood B cells in patients with RA.

Conditions

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Jacques-Olivier Pers · CHRU de Brest

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-01
Primary Completion
2018-01-11
Completion
2018-01-11

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885818 on ClinicalTrials.gov